Valsartan/hydrochlorothiazide

Pharmacology and clinical efficacy

Robyn Kondrack, Syed M. Mohiuddin

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Background: Valsartan/hydrochlorothiazide is a combination of an angiotensin II receptor antagonist and diuretic indicated for hypertensive patients as initial therapy and those not controlled on monotherapy. Objective: To evaluate the pharmacokinetic, pharmacodynamic and clinical efficacy of valsartan/hydrochlorothiazide in hypertension therapy and other cardiovascular outcomes. Methods: Review of current literature. Results: Valsartan/ hydrochlorothiazide has been shown to be superior to its individual components in randomized controlled studies of patients with moderate-to-severe hypertension and in patients who did not respond to monotherapy. When compared to amlodipine, valsartan/hydrochlorothiazide was shown to have a similar rate of the combined outcome of morbidity and mortality. Valsartan/ hydrochlorothiazide has also been studied in specific patient populations, such as diabetics, obese, elderly, black hypertensives and hypertensives with further cardiovascular risk factors, and has been shown to be efficacious in such populations. Conclusion: Valsartan/hydrochlorothiazide has been shown to be an efficacious fixed-dose combination antihypertensive agent that is well tolerated with few side effects.

Original languageEnglish
Pages (from-to)1125-1134
Number of pages10
JournalExpert Opinion on Drug Metabolism and Toxicology
Volume5
Issue number9
DOIs
StatePublished - Sep 2009

Fingerprint

Valsartan
Hydrochlorothiazide
Pharmacology
Pharmacodynamics
Hypertension
Pharmacokinetics
Angiotensin Receptor Antagonists
Diuretics
Antihypertensive Agents
Population
Morbidity

All Science Journal Classification (ASJC) codes

  • Toxicology
  • Pharmacology

Cite this

Valsartan/hydrochlorothiazide : Pharmacology and clinical efficacy. / Kondrack, Robyn; Mohiuddin, Syed M.

In: Expert Opinion on Drug Metabolism and Toxicology, Vol. 5, No. 9, 09.2009, p. 1125-1134.

Research output: Contribution to journalReview article

@article{45ef0ff2b8c848c58611c799a5ee00db,
title = "Valsartan/hydrochlorothiazide: Pharmacology and clinical efficacy",
abstract = "Background: Valsartan/hydrochlorothiazide is a combination of an angiotensin II receptor antagonist and diuretic indicated for hypertensive patients as initial therapy and those not controlled on monotherapy. Objective: To evaluate the pharmacokinetic, pharmacodynamic and clinical efficacy of valsartan/hydrochlorothiazide in hypertension therapy and other cardiovascular outcomes. Methods: Review of current literature. Results: Valsartan/ hydrochlorothiazide has been shown to be superior to its individual components in randomized controlled studies of patients with moderate-to-severe hypertension and in patients who did not respond to monotherapy. When compared to amlodipine, valsartan/hydrochlorothiazide was shown to have a similar rate of the combined outcome of morbidity and mortality. Valsartan/ hydrochlorothiazide has also been studied in specific patient populations, such as diabetics, obese, elderly, black hypertensives and hypertensives with further cardiovascular risk factors, and has been shown to be efficacious in such populations. Conclusion: Valsartan/hydrochlorothiazide has been shown to be an efficacious fixed-dose combination antihypertensive agent that is well tolerated with few side effects.",
author = "Robyn Kondrack and Mohiuddin, {Syed M.}",
year = "2009",
month = "9",
doi = "10.1517/17425250903136730",
language = "English",
volume = "5",
pages = "1125--1134",
journal = "Expert Opinion on Drug Metabolism and Toxicology",
issn = "1742-5255",
publisher = "Informa Healthcare",
number = "9",

}

TY - JOUR

T1 - Valsartan/hydrochlorothiazide

T2 - Pharmacology and clinical efficacy

AU - Kondrack, Robyn

AU - Mohiuddin, Syed M.

PY - 2009/9

Y1 - 2009/9

N2 - Background: Valsartan/hydrochlorothiazide is a combination of an angiotensin II receptor antagonist and diuretic indicated for hypertensive patients as initial therapy and those not controlled on monotherapy. Objective: To evaluate the pharmacokinetic, pharmacodynamic and clinical efficacy of valsartan/hydrochlorothiazide in hypertension therapy and other cardiovascular outcomes. Methods: Review of current literature. Results: Valsartan/ hydrochlorothiazide has been shown to be superior to its individual components in randomized controlled studies of patients with moderate-to-severe hypertension and in patients who did not respond to monotherapy. When compared to amlodipine, valsartan/hydrochlorothiazide was shown to have a similar rate of the combined outcome of morbidity and mortality. Valsartan/ hydrochlorothiazide has also been studied in specific patient populations, such as diabetics, obese, elderly, black hypertensives and hypertensives with further cardiovascular risk factors, and has been shown to be efficacious in such populations. Conclusion: Valsartan/hydrochlorothiazide has been shown to be an efficacious fixed-dose combination antihypertensive agent that is well tolerated with few side effects.

AB - Background: Valsartan/hydrochlorothiazide is a combination of an angiotensin II receptor antagonist and diuretic indicated for hypertensive patients as initial therapy and those not controlled on monotherapy. Objective: To evaluate the pharmacokinetic, pharmacodynamic and clinical efficacy of valsartan/hydrochlorothiazide in hypertension therapy and other cardiovascular outcomes. Methods: Review of current literature. Results: Valsartan/ hydrochlorothiazide has been shown to be superior to its individual components in randomized controlled studies of patients with moderate-to-severe hypertension and in patients who did not respond to monotherapy. When compared to amlodipine, valsartan/hydrochlorothiazide was shown to have a similar rate of the combined outcome of morbidity and mortality. Valsartan/ hydrochlorothiazide has also been studied in specific patient populations, such as diabetics, obese, elderly, black hypertensives and hypertensives with further cardiovascular risk factors, and has been shown to be efficacious in such populations. Conclusion: Valsartan/hydrochlorothiazide has been shown to be an efficacious fixed-dose combination antihypertensive agent that is well tolerated with few side effects.

UR - http://www.scopus.com/inward/record.url?scp=70249083819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70249083819&partnerID=8YFLogxK

U2 - 10.1517/17425250903136730

DO - 10.1517/17425250903136730

M3 - Review article

VL - 5

SP - 1125

EP - 1134

JO - Expert Opinion on Drug Metabolism and Toxicology

JF - Expert Opinion on Drug Metabolism and Toxicology

SN - 1742-5255

IS - 9

ER -